AR033308A1 - Uso de escitalopram enantiomericamente puro - Google Patents

Uso de escitalopram enantiomericamente puro

Info

Publication number
AR033308A1
AR033308A1 ARP020101612A ARP020101612A AR033308A1 AR 033308 A1 AR033308 A1 AR 033308A1 AR P020101612 A ARP020101612 A AR P020101612A AR P020101612 A ARP020101612 A AR P020101612A AR 033308 A1 AR033308 A1 AR 033308A1
Authority
AR
Argentina
Prior art keywords
disorders
disorder
treatment
enantiomerically pure
scitalopram
Prior art date
Application number
ARP020101612A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR033308A1 publication Critical patent/AR033308A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente se relaciona con el uso de escitalopram enantioméricamente puro y/o de medicamentos en dosis bajas del mismo para el tratamiento mejorado de la depresion, en especial el trastorno de depresion mayor, trastornos neuroticos, trastorno de estrés agudo, trastornos de la alimentacion tales como bulimia, anorexia y obesidad, fobias, distimia, síndrome premenstrual, trastornos cognitivos, trastornos del control de los impulsos, trastorno por hiperactividad y déficit de la atencion o drogadiccion. Los medicamentos pueden ser utilizados asimismo en el tratamiento de un trastorno de depresion mayor en pacientes ''resistentes al tratamiento''.
ARP020101612A 2001-05-01 2002-05-02 Uso de escitalopram enantiomericamente puro AR033308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01

Publications (1)

Publication Number Publication Date
AR033308A1 true AR033308A1 (es) 2003-12-10

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101612A AR033308A1 (es) 2001-05-01 2002-05-02 Uso de escitalopram enantiomericamente puro

Country Status (25)

Country Link
US (7) US20040198809A1 (es)
EP (1) EP1385503A1 (es)
JP (1) JP2004527551A (es)
KR (2) KR20100012089A (es)
CN (1) CN1509169A (es)
AR (1) AR033308A1 (es)
AT (1) AT10974U1 (es)
BG (1) BG108379A (es)
BR (1) BR0208283A (es)
CA (1) CA2445843A1 (es)
CZ (1) CZ20033267A3 (es)
EA (1) EA200301195A1 (es)
HR (1) HRP20030744A2 (es)
HU (1) HUP0400054A3 (es)
IL (1) IL158031A0 (es)
IS (1) IS6954A (es)
ME (1) MEP5908A (es)
MX (1) MXPA03008777A (es)
NO (1) NO20034538L (es)
PL (1) PL367480A1 (es)
SK (1) SK14612003A3 (es)
UA (1) UA82828C2 (es)
WO (1) WO2002087566A1 (es)
YU (1) YU85303A (es)
ZA (1) ZA200307102B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1691811B1 (en) * 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
BRPI0617382A2 (pt) 2005-10-14 2017-07-11 H Lundbeck As Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento
US20070112075A1 (en) * 2005-10-14 2007-05-17 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
RU2463039C2 (ru) * 2006-10-20 2012-10-10 Рациофарм Гмбх Эсциталопрам и твердая фармацевтическая композиция, его содержащая
EP2078524B1 (en) * 2006-10-27 2016-08-31 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
EP2185155B1 (en) * 2007-08-03 2017-10-04 Richter Gedeon Nyrt. Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
ES2507517T3 (es) * 2008-01-31 2014-10-15 Takeda Pharmaceutical Company Limited Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
CA2982898C (en) * 2015-05-13 2023-08-29 A. Carlsson Research Ab Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (es) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
KR100411505B1 (ko) * 1998-10-20 2003-12-18 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조방법
ATE237604T1 (de) * 1999-04-14 2003-05-15 Lundbeck & Co As H Verfahren zur herstellung von citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001255654B2 (en) * 2000-04-24 2005-09-22 Aryx Therapeutics Materials and methods for the treatment of depression
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
IL158031A0 (en) 2004-03-28
HUP0400054A2 (hu) 2004-04-28
MXPA03008777A (es) 2004-02-12
ZA200307102B (en) 2004-09-13
AT10974U1 (de) 2010-02-15
NO20034538D0 (no) 2003-10-09
PL367480A1 (en) 2005-02-21
US20040192764A1 (en) 2004-09-30
US20040192765A1 (en) 2004-09-30
BR0208283A (pt) 2004-03-09
BG108379A (bg) 2004-11-30
MEP5908A (xx) 2010-02-10
US20040198809A1 (en) 2004-10-07
UA82828C2 (en) 2008-05-26
EA200301195A1 (ru) 2004-04-29
SK14612003A3 (sk) 2004-04-06
HUP0400054A3 (en) 2007-03-28
WO2002087566A1 (en) 2002-11-07
KR20040030609A (ko) 2004-04-09
NO20034538L (no) 2003-10-09
CN1509169A (zh) 2004-06-30
CA2445843A1 (en) 2002-11-07
JP2004527551A (ja) 2004-09-09
CZ20033267A3 (en) 2004-06-16
IS6954A (is) 2003-09-15
US20040192766A1 (en) 2004-09-30
HRP20030744A2 (en) 2005-06-30
KR20100012089A (ko) 2010-02-05
US20040198810A1 (en) 2004-10-07
US20040198811A1 (en) 2004-10-07
US20080004338A1 (en) 2008-01-03
EP1385503A1 (en) 2004-02-04
YU85303A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
AR033308A1 (es) Uso de escitalopram enantiomericamente puro
NO20100333L (no) Behandling av nevrotiske forstyrrelser
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
ATE410157T1 (de) Modafinil enthaltende zusammensetzung zur behandlung von aufmerksamkeitsdefizitsyndrom/hyperaktivität
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
BR0205684A (pt) Compostos cìclicos fundidos e seu uso medicinal
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
UY28945A1 (es) Derivados de pirrolopiridina
BRPI0414428A (pt) composições farmacêuticas
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
PE20040924A1 (es) Bromhidrato de escitalopram y un metodo para su preparacion
HUP0402619A2 (hu) Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására
BR0206775A (pt) Uso de um medicamento para tratar um indivìduo infectado com hiv, por combinação de imunização com interrupção estruturada do tratamento anti-retrovirótico
AR047715A1 (es) Combinaciones de analepticos y antdepresivos
HUP0300354A2 (hu) HIV immunadjuváns terápia
MXPA05012144A (es) Combinacion del analeptico modafinil y un antidepresivo para el tratamiento de la depresion.
NO20061167L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon
TW200509895A (en) Analeptic and antidepressant combinations
HUP0302293A2 (hu) Rák kezelése aplidin és egy izomvédő szer együttes alkalmazásával
TW200509894A (en) Analeptic and antidepressant combinations
EA200801080A1 (ru) Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
DE60213237D1 (de) Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii
Catherine I am a nurse

Legal Events

Date Code Title Description
FB Suspension of granting procedure